AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

aap Implantate AG

M&A Activity Jun 20, 2007

10_rns_2007-06-20_1aa280df-9bec-4b03-9236-c3bd8941058f.html

M&A Activity

Open in Viewer

Opens in native device viewer

News Details

Ad-hoc | 20 June 2007 12:15

aap Implantate AG: aap focus on implantable biomaterials

aap Implantate AG / Strategic Company Decision

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG, a medical technology company listed in the Prime
Standard Segment on the Frankfurt Stock Exchange and specialized in
biomaterials and implants for trauma and joint reconstruction, will in the
future focus solely on implantable medical biomaterials.

After acquiring the Dutch biomaterials specialist Fame Medical Group, aap
will in 2007 earn more than 70 percent of planned consolidated sales
totaling around EUR 30 million in this segment.

In the months ahead various strategic options will be investigated for the
Trauma/Joint Reconstruction division, located in Berlin. Initially, subject
to approval by the annual meeting of shareholders planned for August 27,
2007, this unit with around 90 employees is to be transferred to a separate
subsidiary. For 2007 aap plans double-digit sales growth in this segment.

For aap, focusing on implantable biomaterials in the core areas bone
cements, bone replacement materials, infection therapy and tissue
generation means concentrating on fast-growing and profitable niche
markets. In these markets aap is already a worldwide technology leader and
has in recent years built up development and sales partnerships with
world-leading orthopedic, spinal column and dental enterprises.

To visualize the realignment aap plans to rename the parent company aap
BioImplants AG.

DGAP 20.06.2007

Language: English
Issuer: aap Implantate AG
Lorenzweg 5
12099 Berlin Deutschland
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: [email protected]
www: www.aap.de
ISIN: DE0005066609
WKN: 506660
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin-Bremen, Hannover, Düsseldorf, Hamburg, München,
Stuttgart

End of News DGAP News-Service


Talk to a Data Expert

Have a question? We'll get back to you promptly.